You are in:Home/Publications/Human mesenchymal stem cell-derived extracellular vesicles/estrogen combined therapy safely ameliorates experimentally induced intrauterine adhesions in a female rat model

Dr. Khalid abd elaziz Mohamed Ibrahem :: Publications:

Title:
Human mesenchymal stem cell-derived extracellular vesicles/estrogen combined therapy safely ameliorates experimentally induced intrauterine adhesions in a female rat model
Authors: Nesrine Ebrahim1,2, Ola Mostafa1, Rania Ebrahim El Dosoky1, Inas A. Ahmed3,4, Ahmed S. Saad5, Abeer Mostafa6,7, Dina Sabry6,7, Khalid Abdelaziz Ibrahim5 and Ayman Samir Farid8
Year: 2018
Keywords: Intrauterine adhesions, UCMSCs-EVs, Estrogen, TNF-α, TGF-β, IL-1, IL-6, RUNX2, Collagen
Journal: Stem Cell Research & Therapy
Volume: 9
Issue: Not Available
Pages: 175
Publisher: Not Available
Local/International: International
Paper Link:
Full paper Khalid abd elaziz Mohamed Ibrahem_s13287-018-0924-z.pdf
Supplementary materials Not Available
Abstract:

Background: Mesenchymal stem cells (MSCs) have diverse functions in regulating injury and inflammation through the secretion of extracellular vesicles (EVs). Methods: In this study, we investigated the systemic administration of extracellular vesicles derived from human umbilical cord mesenchymal stem cells (UCMSCs-EVs) as a therapeutic agent for intrauterine adhesions (IUAs) caused by endometrial injury. Additionally, we investigated the therapeutic impact of both UCMSCs-EVs and estrogen either separately or in combination in a rat model. The inflammation, vascularization, proliferation, and extent of fibrosis were assessed by a histopathological and immunohistochemical assessment using transforming growth factor (TGF)-β as a fibrotic marker and vascular endothelial growth factor (VEGF) as a vascular marker. Additionally, quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 (inflammatory cytokines), CD140b (a marker of endometrial stem cells), and RUNX2 (an antifibrotic factor). Finally, Western blotting was used to evaluate collagen I and β-actin expression. Results: The therapeutic groups treated with either UCMSCs-EVs alone or combined with estrogen exhibited a significant decrease in inflammation and fibrosis (TNF-α, TGF-β, IL-1, IL-6, RUNX2, and collagen-I) as well as a significant decrease in vascularization (VEGF) compared with the untreated rats with IUAs. The most significant results were obtained in animals with IUAs that received a combined therapy of UCMSCs-EVs and estrogen. Conclusions: We conclude that the synergistic action of human UCMSCs-EVs combined with estrogen provides a highly effective alternative regenerative agent in IUA treatment.

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus